| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/29/2005 | US6872711 β-substituted β-aminoethyl phosphonate derivatives |
| 03/29/2005 | US6872700 Methods for glucagon suppression |
| 03/29/2005 | US6872390 Local anesthetic methods and kits |
| 03/29/2005 | CA2392879C A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| 03/29/2005 | CA2195745C Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| 03/29/2005 | CA2170772C Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
| 03/29/2005 | CA1341477C Method of reducing immunoglobulin e responses |
| 03/24/2005 | WO2005026783A2 Method for configuring air-core photonic-bandgap fibers free of surface modes |
| 03/24/2005 | WO2005026353A1 Method of evaluating cancerization degree |
| 03/24/2005 | WO2005026351A1 Method of evaluating cancerization degree |
| 03/24/2005 | WO2005026350A1 Method of evaluating cancerization degree |
| 03/24/2005 | WO2005026344A1 Method and kit for detecting proliferative diseases causing sclerosis, preventive and/or remedy for proliferative diseases causing sclerosis and method and kit for identifying substance efficacious in preventing and/or treating proliferative diseases causing sclerosis |
| 03/24/2005 | WO2005026318A2 Methods and compositions for producing antigenic responses |
| 03/24/2005 | WO2005025675A1 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| 03/24/2005 | WO2005025674A1 Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias |
| 03/24/2005 | WO2005025673A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 03/24/2005 | WO2005025621A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 03/24/2005 | WO2005025620A2 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents |
| 03/24/2005 | WO2005025619A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | WO2005025605A1 Remedy and therapeutic method for periodontal diseases and pulpal diseases |
| 03/24/2005 | WO2005025589A1 Composition and method for facilitating bone healing |
| 03/24/2005 | WO2005025582A1 Antibacterial compositions of n-acetyl-d-aminoglycosamine and antibiotics |
| 03/24/2005 | WO2005025579A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 03/24/2005 | WO2005025574A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. |
| 03/24/2005 | WO2005025571A1 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug. |
| 03/24/2005 | WO2005025567A1 Benzothiazole derivatives for the treatment of diabetes |
| 03/24/2005 | WO2005025565A1 Microbicide composition comprising a minor groove binder optionally in combination with an anti-hiv compound and use thereof in the prevention of sexually transmitted diseases |
| 03/24/2005 | WO2005025563A1 Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
| 03/24/2005 | WO2005025538A1 Composition for medical use containing sugar chain-containing chitosan derivative and glycosaminoglycan |
| 03/24/2005 | WO2005025501A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 03/24/2005 | WO2005025500A2 Process for preparing water soluble diterpenes and their applications |
| 03/24/2005 | WO2005025490A2 Novel polyol macrolide antitumor-antibiotics from the novel marine actinomycete strain cnq140 |
| 03/24/2005 | WO2005011614A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 03/24/2005 | WO2005004942A3 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 03/24/2005 | WO2005000324A3 Colloidal silver composition having antimicrobial properties |
| 03/24/2005 | WO2004110417A3 Compositions for the enhanced treatment of depression |
| 03/24/2005 | WO2004108747A3 Lectin conjugates |
| 03/24/2005 | WO2004098618A3 Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions |
| 03/24/2005 | WO2004098509A3 Compositions for inducing immune responses |
| 03/24/2005 | WO2004091546A3 Central nervous system stimulant and opioid antagonist combinations |
| 03/24/2005 | WO2004091489A3 Topical blood pressure composition |
| 03/24/2005 | WO2004067554A3 Compositions and methods of tolerizing a primate to an antigen |
| 03/24/2005 | WO2004066978A8 Powder pharmaceutical compositions |
| 03/24/2005 | WO2004066956A3 Uses of integrin alphavbeta3 antagonists |
| 03/24/2005 | WO2004043338A3 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 03/24/2005 | WO2004025270A3 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis |
| 03/24/2005 | WO2004017948A8 Use of lck inhibitor for treatment of immunologic diseases |
| 03/24/2005 | WO2004000197A3 Quick dissolve compositions and tablets based thereon |
| 03/24/2005 | WO2003103478A3 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 03/24/2005 | WO2003099217A3 Methods of treating bacterial infections and diseases associated therewith |
| 03/24/2005 | WO2003094856A3 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
| 03/24/2005 | WO2003090687A9 Using heat shock proteins to increase immune response |
| 03/24/2005 | WO2003083067A3 Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| 03/24/2005 | WO2003082208A8 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
| 03/24/2005 | WO2003077861A3 Water-based delivery systems |
| 03/24/2005 | WO2003059291A3 Treatment of bone disorders with skeletal anabolic drugs |
| 03/24/2005 | WO2002092759A9 Molecules for disease detection and treatment |
| 03/24/2005 | WO2002058450A3 Regulation of cell growth by muc1 |
| 03/24/2005 | US20050066378 Transgenic animal comprising gene which induces lymphoproliferation for use as tool in generating autoantibodies for detection and treatment of autoimmune diseases; immunotherapy |
| 03/24/2005 | US20050065340 Psychological disorders; anxiolytic agents; antidepressants; analgesics ; schizophrenia |
| 03/24/2005 | US20050065339 Amino-alkyl derivatives |
| 03/24/2005 | US20050065319 Combination method for treating viral infections |
| 03/24/2005 | US20050065209 Citalopram for the treatment of elevated blood pressure |
| 03/24/2005 | US20050065205 Administering protein kinase C activator such as macrocyclic lactone; mixture with enzyme inhibitor and carrier |
| 03/24/2005 | US20050065196 Azole compound and medicinal use thereof |
| 03/24/2005 | US20050065176 Combinations |
| 03/24/2005 | US20050065164 Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| 03/24/2005 | US20050065161 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| 03/24/2005 | US20050065159 Penis enlargement |
| 03/24/2005 | US20050065158 Using cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitor; sunergistic mixture with histamine h-3 antagonist |
| 03/24/2005 | US20050065154 Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents |
| 03/24/2005 | US20050065152 1-Adamantyl chalcones for the treatment of proliferative disorders |
| 03/24/2005 | US20050065133 Synergistic mixture; bone disorders; osteoporosis ; anticancer agents; obesity |
| 03/24/2005 | US20050065121 Using probucol ester |
| 03/24/2005 | US20050065114 Antitumor, anticancer agents; viricides; bactericides; fungicides; immunology stimulants |
| 03/24/2005 | US20050065113 Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments |
| 03/24/2005 | US20050065110 Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents |
| 03/24/2005 | US20050065102 Medicinal compositions |
| 03/24/2005 | US20050065094 Synergistic mixture with other drug; side effect reduction |
| 03/24/2005 | US20050065086 Adjust drug releasing characteristics, bioavailability of oral drug |
| 03/24/2005 | US20050064593 Expression vector comprising breast cancer gene (BCL-2) nucleotide sequences for use as tool in treatment, diagnosis and prevention of cell proliferative disorders |
| 03/24/2005 | US20050064588 Epidermal melanocyte culture formulations |
| 03/24/2005 | US20050064572 Lipid kinase |
| 03/24/2005 | US20050064543 Secreted proteins |
| 03/24/2005 | US20050064542 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 03/24/2005 | US20050064534 Using microscopic systems to monitoring f-actin and myosin activity in cells; monitoring biopolymer transfer between membrane walls |
| 03/24/2005 | US20050064530 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 03/24/2005 | US20050064527 Identifying modulator of activity of newly identified multiple antibiotic resistance (mar) locus regulated (NIMR) gene products; microbiocides; bactericides |
| 03/24/2005 | US20050064522 EG-VEGF nucleic acids and polypeptides and methods of use |
| 03/24/2005 | US20050064491 Transport protein for use as tool in identifying modulator for treatment of sleep, nervous suystem, anixety, eating, cardiovascular and pain disordere |
| 03/24/2005 | US20050064416 Methods for diagnosing and treating heart disease |
| 03/24/2005 | US20050064407 Bcl-2 dnazymes |
| 03/24/2005 | US20050064404 Regulation of human serotonin-like g protein-coupled receptor |
| 03/24/2005 | US20050064043 Ingesting a combination of dosage form of liquid, ingested in a series of sequential dosage: a first dose of bisacodyl;) a 2nd dose in a combination of bisacodyl, metoclopramide, a phosphorus compound and sodium, 3rd dose of phosphorus compounds and sodium, 4th dose of metoclopramide |
| 03/24/2005 | US20050064032 Dosage form, device, and methods of treatment |
| 03/24/2005 | US20050064031 Combination contraceptive, kits that contain the latter, and a method that uses the latter |
| 03/24/2005 | US20050064027 Prolonged gastric retention time due to bioadhesion (which may be polymers, metal oxides, or ligands for specific mucosal components); macrospheres for delivery of acyclovir for example |
| 03/24/2005 | US20050064025 With a phospholipid such as dipalmitoyl phosphatidylcholine, and an antiinflammatory drug such as a nonsteroidal, anti-inflammatory drug (NSAID) such as celecoxib |
| 03/24/2005 | US20050064017 feeding dog or cat the pet food including 5-40% by weight protein, 5-45% by weight fat, 0.1 to 12% by weight fiber, 1 to 90% by weight digestible carbohydrate, 0.1-2% by weight functional ingredient to build lean muscle mass |
| 03/24/2005 | US20050064008 Solid or semi-solid therapeutic formulations |